Background The nasopharynx can from time to time accommodate otherwise pathogenic
bacteria. This phenomenon is called asymptomatic carriage. However, in case of decreased …

In Japan, the 7-valent pneumococcal conjugate vaccine (PCV7) was introduced to the
nation's routine immunization program in April 2013 and was replaced by the 13-valent …

Background Pneumococcus is exposed to a variety of temperature and oxygen levels in the
upper respiratory tract and as it invades the lung, tissues, and blood. We sought to …

Introduction: By preventing nasopharyngeal carriage acquisition among vaccinated persons,
and thus reducing transmission, pneumococcal conjugate vaccines (PCVs) provide …

Although mean efficacy of multivalent pneumococcus vaccines has been intensively studied,
variance in vaccine efficacy (VE) has been overlooked. Different net individual protection …

The separation of pneumococcal serotypes from a complex polymicrobial mixture may be
required for different applications. For instance, a minority strain could be present at a low …

Aims: To determine the prevalence of nasopharyngeal carriage of Streptococcus
pneumoniae in healthy children aged 0-6 years who were vaccinated with pneumococcal …

Antimicrobial resistance is an emerging public health concern. Ten-valent pneumococcal
vaccine (PCV10) was introduced in Pakistan's Expanded Program on Immunization (EPI) in …

Abstract In November 2013, a 13-valent pneumococcal conjugate vaccine (PCV13) for all
infants aged younger than 5 years was incorporated into the Japan national immunization …

Young children–the main asymptomatic carriers of pneumococcus–are often the source of
pneumococcal infections. PCV13 replaced PCV7 in 2010 in Hungary and it became a …